What happened?

After testing positive for the coronavirus, the Brazilian president Bolsonaro publicly took a tablet of the malaria drug hydroxychloroquine. This drug, however, has not proved effective against COVID-19 and its use against it is not approved anywhere in the world. This move, alongside President Trump’s embrace of the drug, illustrates how politicized research into this drug has become and how a next step has been taken towards the politicization of science as we know it.

What does this mean?

From now on, we should be mindful of the fact that any study may be called into question and that this will be increasingly based on the intentions and underlying interests of the researcher. Sometimes, we are right to doubt; we know, for example, that funding, even in medicine research, can influence research findings (i.e. funding bias). However, we seem to be taking it a step further, which is diminishing our shared knowledge base. As a consequence, in the future attempts to combat fake news (and the broader infocalypse) could become even more futile than they are now.

What’s next?

And yet, it’s understandable that health insurers want to bond more with consumers and to have a more proactive role in the health of their customers. To a health insurer, more data on patients and treatments equals more possibilities to organize care more efficiently and cost-effectively for society. That’s why insurers are seeking alliances to improve their customer retention through cooperation. Big tech companies are crucial in appealing to the homo ludens and promoting a vital lifestyle. Better adjustment to the services and ecosystem of big tech, as for example Vitality health is adjusted to Apple Watches, appears to be a strategic route. To generate trust and security around health data, insurers are more focused on cooperation within the healthcare domain. Digital companies such as CareVoice or apps such as Stresscoach and MS Sherpa could fulfill an important role for the insurer, but caution remains warranted regarding their revenue model and the responsible use of health data.